Molecular analysis of **SRD5A2** a novel homozygous variant found in a Mexican family

**Morales Rios LC**; **Calvo Anguiano G**; **Martínez de Villarreal LE**; **Villarreal Pérez JZ**; **Castillo Castro C**; **Lugo Trampe JJ**; **García Castañeda GB**; **López Uriarte GA***

*Department of Genetics, University Hospital “Dr. José E. González” UANL, Monterrey, Nuevo Leon 64460, Mexico.

**Abstract**

5-alpha-Reductase deficiency is one of the causes involving disorders of sex development 46, XY. Mutations in **SRD5A2** gene lead to a wide clinical manifestation, sometimes not giving a clear outlook for a clinical diagnosis, making molecular diagnosis an important diagnostic pillar of these conditions. Here, we show the importance of molecular and pedigree analysis for diagnosis and adequate genetic counseling.

**Keywords**: 46, XY disorder of sex development; ambiguous genitalia; 5-alpha-Reductase type 2; novel mutation.

**Abbreviations**: T: Testosterone; DHT: Dihydrotestosterone; DSD: Disorder of Sex Development.

In Mexico has been reported a P212R substitution that is believed to be a founder variant in the Mexican population [5]. Nevertheless, in this study, we describe the molecular diagnosis of **SRD5A2** gene in a Mexican family and analyze the family pedigree, finding a novel variant involving the exon 4.

**Case presentation**

A 24 years old female was referred to the Genetics Department for presenting primary amenorrhea and a 46,XY karyotype. She has a clinical history of bartolinitis at 12 years old, unilateral gonadectomy at 16 years old with a histopathological report compatible with testicular tissue. At physical exploration, we found no facial dysmorphism, short neck with acanthosis nigricans, breast development with a Tanner 2 stage, panniculus adipose in the abdomen, suprapubic surgical scar, fine pubic hair, labia majora covering the labia minora, clitoris with central urethral meatus, visible vaginal introitus and absence of axillary hair. The patient identifies as female and her sexual orientation is bisexual. Within laboratory and imaging studies total testos-

After performing the medical history and family pedigree a molecular analysis was made. It was performed to the whole family. Genomic DNA was extracted from peripheral blood lymphocytes with Puregene kit (© Qiagen) following the manufacturer’s instructions. Primer-BLAST (NCBI) was used to design primers. The coding regions of the SRD5A2 gene were amplified by PCR, and direct sequencing was performed using the BigDye Terminator v 3.1 Kit (Applied Biosystems) on an ABI3130 genetic analyzer (Applied Biosystems®). Primers were designed to amplify the ~ 50 bp flanking regions at both ends of each exon. Exon 4 did not amplify, primers flanking ~ 500, 1000 and 1500 bp were redesigned on both ends of exon 4 (introns 3 and 4).

The generated sequences were compared with the reference sequence (NM_000348.4) (Figure 1).

Figure 1: A. Primers flanking ~ 50 bp at both ends of each exon. B. Redesign of primers expanding coverage to intronic region, including electrophoresis for each new primer. M: marker, Px: patient, (N): normal, (-) negative.

Figure 2: A. Electropherogram showing the homozygous 1605 bp deletion, corresponding from amino acid 206 to 226, belonging to one of the transmembrane regions of the protein.

Figure 3: A. Elecrophoresis of the whole family, showing individuals 1 (proband) and 3 (sister) with the homozygous deletion. B. Electropherogram of every member of the family, 1 and 3 homozygous deletion, 2, 4, 5 heterozygous carriers of the deletion.

Figure 4: A. Normal protein conformation. B. Resulting protein from analyzing the variant, loss of transmembrane domain from 206-226 amino acid.
We found a 1605 bp deletion, which corresponds to amino acid 206 to 226, belonging to one of the transmembrane regions of the gene. Once we had localized the mutation, we search it directly in each family member (Figures 2,3).

By using PyMOL, a molecular visualization system, we introduced the variant to analyze the impact in the conformation of the protein, we detect an almost whole helix loss (Figure 4).

Discussion

In our study, we analyze a family that comes from a small town in central Mexico that has a history of endogamy. Firstly, we began the approach with our proband, her clinical history was compatible with a DSD XY, the history of endogamy led us to begin with the molecular analysis of SRD5A2, being conscious of on differential diagnosis was androgen insensitivity.

During molecular analysis, we didn’t obtain an amplification of exon 4, the coverage towards introns was expanded to locate the cut-off point, identifying a deletion in a homozygous state, which has not been reported in the literature, nor in different databases (ClinVar, VarSome, Ensemble, HGMD) for what is considered a novel variant.

Once we had the molecular diagnosis, knowing that this condition is inherited as an autosomal recessive mode, we expanded the molecular analysis to the family, trying to find asymptomatic carriers (50%), affected individuals (25%), individuals without the mutation (25%). Doing the pedigree analysis, as expected, both parents were heterozygous carriers, like the brother. The sister of the patients with proven fertility has like our patient homozygous deletion, it has been described that females 46,XX are fertile, have a normal internal and external genitalia development, sometimes delayed menarche, reduce body hair [2].

The approach of patients with this condition doesn’t end with the molecular diagnosis, it is necessary to continue with complementary functional studies to determine the conformation of the protein and assess its function.

Conclusion

The implementation of a complementary molecular strategy for the analysis of the gene involved in DSD XY, which already had a clinical, biochemical and histopathological diagnosis, is of utmost importance to confirm the specific diagnosis, explain the pathophysiology, provide adequate transdisciplinary management of the patient and grant genetic counseling to her and her family.

Declarations

Conflict of interest: None declared.

Funding: Genetics Department University Hospital “Dr. José E. González,” UANL, Monterrey, Nuevo León, México.

References